-Ethicon introduces ETHIZIA™ hemostatic sealing patch, clinically proven to stop disruptive bleeding
The addition of the hemostatic patch complements Ethicon’s comprehensive biosurgery portfolio and its ability to address critical unmet needs in hemorrhage control.
RARITAN, N.J., Nov. 16, 2023 /PRNewswire/ — Ethicon*, a Johnson Company
The ETHIZIA™ Hemostatic Sealing Patch has received CE Mark approval as an adjunctive hemostatic for breakthrough bleeding in internal organs, except cardiovascular and neurological, and is expected to launch in EMEA in Q1 2024 and other key markets in the Americas. North, APAC and LATAM following regulatory approvals.
“As a global leader in surgery, we are committed to empowering healthcare providers to protect patients from surgical complications through continuous delivery of innovative solutions,” said Vladimir Makatsaria, President of the Ethicon Business Group. “Interrupted bleeding can contribute to serious complications and, with the addition of ETHIZIA™ to our portfolio, we are well positioned to provide critical hemostasis solutions for patients.”
In May 2022, Ethicon acquired GATT Technologies B.V., a Netherlands-based company that uses differentiated synthetic polymers to create hemostatic and sealant products to address complex surgical bleeding and leak problems. The acquisition of GATT and the addition of its synthetic technology complements Ethicon’s current capabilities, enabling the development of innovative solutions that address critical unmet needs, such as the ETHIZIA™ hemostatic sealing patch, which can deliver sustained hemostasis in emergency situations. difficult to control bleeding.
As a global leader in surgery, Ethicon leverages its deep expertise to design surgical solutions that are smarter, less invasive and more personalized. The introduction of ETHIZIA™ provides a unique design that surgeons can rely on to work equally effectively on both sides***8, giving surgeons the confidence they need in any surgical situation.
About Ethicon
At Ethicon, a Johnson company
About Johnson
En Johnson
Forward-looking statements
This press release contains “forward-looking statements,” as defined in the Private Securities Litigation Reform Act of 1995, regarding the ETHIZIATM supplemental hemostatic solution. The reader is cautioned not to place reliance on these forward-looking statements. These statements are based on current expectations about future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Ethicon, Inc., Ethicon Endo-Surgery, LLC, Johnson
*Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates. All other trademarks are the property of their respective owners.
**Johnson
***Preclinical test data are not necessarily indicative of clinical performance.
****Based on clinical trial data. The full analysis set showed that 32/39 patients (82%) achieved hemostasis within 30 seconds.
*****Tachosil Fibrin Sealant Patch is a leader in the EMEA region based on market share data. Tachosil time to hemostasis is 3 minutes per IFU.
Media Contact: Paloma FelicianoPFelici1@its.jnj.com
Investor Contact:Sarah WoodInvestor-relations@its.jnj.com
©Ethicon US, LLC. 2023. All rights reserved.
Logo – https://mma.prnewswire.com/media/2268164…
View original content: https://www.prnewswire.com/news-releases/ethicon-presenta-el-parche-de-sellado-hemostatico-ethizia-para-detener-el-sangrado-perturbador-301991183.html
